Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract

RULE 19.6(c) CONFIRMATION WITH RESPECT TO STATED POST-OFFER INTENTIONS WITH REGARD TO HVIVO PLC

Successful extension of contract underpins 2021 revenue growth expectations

Cathal Friel, Executive Chairman of Open Orphan, said: We are delighted to announce, further to our announcement in July, the Codagenix intranasal, single dose COVID-19 vaccine candidate has received MHRA

This RNS announces two very exciting deals that our Open Orphan subsidiary Venn Life Sciences has been awarded, from both our Paris office and Breda office in the Netherlands.

Open Orphan, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is

Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model